ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,487.03
0.25%
Dow Jones
38,834.86
0.15%
US Dollar vs MXN
18.44485
0.06%
Brent Oil
84.545
-0.18%
Bitcoin
65,156.18
0.29%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. AbCellera Biologics Inc (ABCL)

  7. AbCellera Biologics Inc (ABCL) Noticias

ABCL

AbCellera Biologics (ABCL)

AbCellera Biologics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ABCL
FechaHoraFuenteTítuloSímboloCompañía
13/06/202415:53Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABCLAbCellera Biologics Inc
03/06/202415:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABCLAbCellera Biologics Inc
28/05/202415:05Business WireAbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024NASDAQ:ABCLAbCellera Biologics Inc
07/05/202415:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABCLAbCellera Biologics Inc
07/05/202415:05Business WireAbCellera Reports Q1 2024 Business ResultsNASDAQ:ABCLAbCellera Biologics Inc
01/05/202408:00Business WireAbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech CompaniesNASDAQ:ABCLAbCellera Biologics Inc
08/04/202411:05Business WireAbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024NASDAQ:ABCLAbCellera Biologics Inc
03/04/202415:05Business WireAbCellera to Report First Quarter 2024 Financial Results on May 7, 2024NASDAQ:ABCLAbCellera Biologics Inc
19/03/202415:05Business WireAbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024NASDAQ:ABCLAbCellera Biologics Inc
11/03/202408:00Business WireAbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological ConditionsNASDAQ:ABCLAbCellera Biologics Inc
05/03/202415:30Business WireAbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024NASDAQ:ABCLAbCellera Biologics Inc
23/02/202415:30Business WireAbCellera Announces Resignation of Board MemberNASDAQ:ABCLAbCellera Biologics Inc
22/02/202419:15Business WireAbCellera to Present at Upcoming Investor Conferences in MarchNASDAQ:ABCLAbCellera Biologics Inc
20/02/202415:49Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ABCLAbCellera Biologics Inc
20/02/202415:05Business WireAbCellera Reports Full Year 2023 Business ResultsNASDAQ:ABCLAbCellera Biologics Inc
23/01/202415:05Business WireAbCellera to Report Full Year 2023 Financial Results on February 20, 2024NASDAQ:ABCLAbCellera Biologics Inc
20/12/202315:05Business WireAbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024NASDAQ:ABCLAbCellera Biologics Inc
16/11/202315:05Business WireAbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023NASDAQ:ABCLAbCellera Biologics Inc
03/11/202311:05Business WireAbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023NASDAQ:ABCLAbCellera Biologics Inc
02/11/202315:05Business WireAbCellera Reports Q3 2023 Business ResultsNASDAQ:ABCLAbCellera Biologics Inc
01/11/202315:05Business WirePrelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:ABCLAbCellera Biologics Inc
31/10/202315:05Business WireAbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023NASDAQ:ABCLAbCellera Biologics Inc
11/10/202315:05Business WireAbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023NASDAQ:ABCLAbCellera Biologics Inc
27/09/202308:00Business WireAbCellera Announces Two T-Cell Engager Presentations at SITC 2023NASDAQ:ABCLAbCellera Biologics Inc
20/09/202316:02Business WireAbCellera Expands Multi-Target Antibody Discovery Collaboration with RegeneronNASDAQ:ABCLAbCellera Biologics Inc
13/09/202308:00Business WireAbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in OncologyNASDAQ:ABCLAbCellera Biologics Inc
03/08/202315:05Business WireAbCellera Reports Q2 2023 Business ResultsNASDAQ:ABCLAbCellera Biologics Inc
24/07/202315:05Business WireAbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for RehearingNASDAQ:ABCLAbCellera Biologics Inc
06/07/202315:05Business WireAbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023NASDAQ:ABCLAbCellera Biologics Inc
30/05/202312:15Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ABCLAbCellera Biologics Inc
 Showing the most relevant articles for your search:NASDAQ:ABCL

Su Consulta Reciente

BIT
P1YZB6
NLBNPIT1YZB6 20991231 17...
BIT
P1YD33
NLBNPIT1YD33 20991231 88...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados